Accessibility Menu
 

Eupraxia Pharmaceuticals

(NASDAQ) EPRX

Current Price$7.89
Market Cap$485.26M
Since IPO (2021)+183%
5 YearN/A
1 Year+104%
1 Month+8%

Eupraxia Pharmaceuticals Financials at a Glance

Market Cap

$485.26M

Revenue (TTM)

$0.00

Net Income (TTM)

$47.35M

EPS (TTM)

$-0.99

P/E Ratio

-7.96

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$7.89

Volume

266,136.665

Open

$7.81

Previous Close

$7.89

Daily Range

$7.81 - $8.13

52-Week Range

$3.67 - $9.32

EPRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eupraxia Pharmaceuticals

Industry

Biotechnology

Employees

21

CEO

James A. Helliwell, MD

Headquarters

Victoria, BC V8R 5G4, CA

EPRX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-67%

Return on Capital

-51%

Return on Assets

-48%

Earnings Yield

-12.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$485.26M

Shares Outstanding

61.50M

Volume

266.14K

Avg. Volume

225.50K

Financials (TTM)

Gross Profit

$241.68K

Operating Income

$39.07M

EBITDA

$38.83M

Operating Cash Flow

$29.03M

Capital Expenditure

$598.77K

Free Cash Flow

$29.63M

Cash & ST Invst.

$80.35M

Total Debt

$153.95K

Eupraxia Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$73.86K

N/A

Gross Margin

0.00%

N/A

Market Cap

$485.26M

N/A

Market Cap/Employee

$14.70M

N/A

Employees

33

N/A

Net Income

$16.95M

-57.0%

EBITDA

$16.32M

-51.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$80.20M

+142.8%

Accounts Receivable

$672.45K

+193.8%

Inventory

$0.00

N/A

Long Term Debt

$75.71K

N/A

Short Term Debt

$185.90K

+158.7%

Return on Assets

-47.95%

N/A

Return on Invested Capital

-51.36%

N/A

Free Cash Flow

$10.07M

-67.5%

Operating Cash Flow

$9.88M

-65.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNFTGenfit S.A.
$8.95+4.07%
NAUTNautilus Biotechnology, Inc.
$2.70+2.66%
SLSSELLAS Life Sciences Group, Inc.
$4.93-0.40%
IVAInventiva S.A.
$4.99-2.73%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$99.60+0.05%
NVDANvidia
$198.61-0.00%
AAPLApple
$280.19+0.03%
TSLATesla
$390.97+0.02%

Questions About EPRX

What is the current price of Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals is trading at $7.89 per share.

What is the 52-week range for Eupraxia Pharmaceuticals?

Over the past 52 weeks, Eupraxia Pharmaceuticals has traded between $3.67 and $9.32.

How much debt does Eupraxia Pharmaceuticals have?

As of the most recent reporting period, Eupraxia Pharmaceuticals reported total debt of $154,362.

How much cash does Eupraxia Pharmaceuticals have on hand?

Eupraxia Pharmaceuticals reported $80.56M in cash and cash equivalents in its most recent financial results.

What is Eupraxia Pharmaceuticals’s dividend yield?

Eupraxia Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.